Oral Tablet Immunotherapy for Allergic Rhinitis: Advancing Management in the Pediatric Setting – American Academy of Pediatrics: California

Join Dr. Lawrence DuBuske for a Live CME Lecture on Allergic Rhinitis!

Date: Saturday, December 9, 2023

3:00 PM – 4:15 PM PDT: AR Presentation
4:15 PM – 4:30 PM PDT: Question & Answer Session/Closing Remarks


Emperors Ballroom I
Caesar’s Palace
3570 S Las Vegas Blvd
Las Vegas, NV 89109


This activity is provided by Integrity Continuing Education, Inc.


This activity is supported by an educational grant from ALK-Abello, Inc.


Allergic Rhinitis (AR) in children and adolescents is a commonly misunderstood, misdiagnosed, and mistreated condition. AR and AR with conjunctivitis (ARC) exerts significant effect on quality of life and has deleterious effects on sleep, academic performance, family functioning, and involvement in outdoor activities. Fortunately, there have been advances in the diagnosis and treatment of AR and ARC that support improved diagnosis and care of patients with inadequate relief from symptom-relieving therapies, including broadly available specific IgE tests, advances in understanding of immune mechanisms, and newer allergen immunotherapies including oral tablet immunotherapy.

Join Dr. DuBuske as he reviews these important updates to provide clinicians with the knowledge and skills to provide care of children and adolescents with AR and ARC that is aligned with the latest evidence and best-practices.


Lawrence M. DuBuske, MD
George Washington University Hospital
Clinical Professor of Medicine
The George Washington University School of Medicine and Health Sciences (2010-2021)
Washington, District of Columbia


This educational initiative has been designed for pediatricians and pediatric NPs and PAs in pediatric care settings who care for and manage patients with AR and ARC.


Upon completion of this educational activity, participants should be able to:

  • Discuss the burden of symptoms of AR and ARC and the associated impacts on quality of life in children and adolescents
  • Implement strategies for the early diagnosis and optimal assessment of AR and ARC in the pediatric setting
  • Describe the role of allergy immunotherapy in the management of patients with AR and ARC
  • Utilize available therapies to achieve optimal management of pediatric patients with AR and ARC


There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • View the live presentation
  • Complete the posttest evaluation form at the end of the program

Your certificate will be sent to you within four weeks of receipt of the completed evaluation.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


There is no registration fee for attending this symposium; however, seating is limited. Preregistration does not guarantee seating. We do recommend arriving at the satellite symposium location early.


Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Olivia Benevento prior to the live event at (855)-835-4004.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Lawrence M. DuBuske, MD
Board: Abionics, ALK-Abello, Allergy Therapeutics, AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi
Speaker: ALK-Abello, AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Research: Abionics, AstraZeneca, Regeneron

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


3:00 PM – 4:15 PM PDT: AR Presentation
4:15 PM – 4:30 PM PDT: Question & Answer Session/Closing Remarks

There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 1.5 AMA PRA Category 1 CME creditsTM. To do so, you must participate in the live presentation and complete the posttest and evaluation following the event. A statement of credit will be issued within 4 weeks of submission of a completed activity evaluation form.